The Danish company has forecast overall revenue of approximately DKK 30 (US$4.9 million) for 2021 BioPorto said that, in the first quarter, it pushed hard on clinical programs for its NGAL Test for pediatric acute kidney injury and a coronavirus test
BioPorto A/S (CPH:BIOPOR) (FRA:2P4) has shared an interim report which showed that its first-quarter 2021 revenue grew by 33% driven by “strong sales of antibodies” and its flagship NGAL acute kidney-injury test.
The in-vitro diagnostic company based in Hellerup, Denmark, said that revenue from product sales of its proprietary NGAL Test remained at last year’s “high level” with a “solid performance” in the United States.
Larsen had served as CFO and a member of the company’s management team since 2018 The search for a successor will be initiated immediately
BioPorto A/S (CPH:BIOPOR) (FRA:2P4) announced that it has begun a search for a new CFO after Ole Larsen resigned to pursue opportunities outside the company.
Larsen had served as CFO and a member of the company’s management team since 2018. He will officially leave the company by the end of May and remain available for the company until the end of October.
“It is with regret that we received Ole’s resignation,” CEO Peter Mørch Eriksen said in a statement. “He has been a truly important asset for BioPorto. During his three-year tenure, he has established a strong performing finance organization while focusing on broadening our investor reach and dialogue, which has been pivotal in execution of our funding strategy. I am grateful for his strong contribution and wish him all the best in his future endeavors.”